:max_bytes(150000):strip_icc():focal(644x399:646x401)/Ozempic-injection-101822-f89ffa28671841cdb26ddb53f2b48803.jpg)
PEOPLE spoke with Ania Jastreboff M.D., PhD., an obesity medicine physician scientist at Yale University to better understand Wegovy and Ozempic| People.com
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize| U.S. Food and Drug Administration
Learn how navigating drug shortages impacts care, delays treatments, and affects outcomes–and what can be done to address this growing challenge.| Xevant
KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.| KFF